SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report
                 (Date of earliest event reported): June 9, 2004

                           ARIAD PHARMACEUTICALS, INC.
             (Exact Name of Registrant as Specified in its Charter)


Delaware                             0-21696                      22-3106987
(State or Other Jurisdiction    (Commission File Number)   (I.R.S. Employer
of Incorporation)                                           Identification No.)


                              26 LANDSDOWNE STREET
                         CAMBRIDGE, MASSACHUSETTS 02139
              (Address of principal executive offices and zip code)


               Registrant's telephone number, including area code:
                                 (617) 494-0400





ITEM 5.    OTHER EVENTS

           On June 9, 2004, the Registrant disseminated a Press Release
           announcing that the telephone number for U.S. investors wishing to
           listen to the upcoming analyst conference call to be hosted by the
           Company on June 15, 2004 has been revised. The revised telephone
           number is 888-482-0024. All other telephone numbers, as well as the
           pass code numbers, in today's earlier press release announcing the
           analyst conference call remain unchanged.

           The information contained in the Press Release dated June 9, 2004, is
           incorporated herein by reference and attached as Exhibit 99.1 hereto.

ITEM 7.    FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.


           (c)    Exhibits.

                  99.1     The Registrant's Press Release dated June 9, 2004.



                                   Signatures

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                        ARIAD PHARMACEUTICALS, INC.



                                        By:    /s/ Edward M. Fitzgerald
                                               ------------------------
                                               Edward M. Fitzgerald
                                               Senior Vice President and
                                                Chief Financial Officer


Date:    June 9, 2004


                                       2




                                  EXHIBIT INDEX
                                  -------------

Exhibit
Number          Description                         Sequential Page Number
-------         -----------                         ---------------------------

99.1            The Registrant's Press Release                  4
                dated June 9, 2004.


                                       3